secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2023-02-14T23:59:59+00:00
Accession:  0001104659-23-020220
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma enters amended employment agreements with CEO Josh Disbrow and CFO Mark Oki
--------------------------------------------------------------------------------

- CEO Disbrow’s agreement amended to one-year terms with auto-renewal; change of control acceleration requires termination within 12 months.
- CFO Oki’s agreement modified to conform equity acceleration and Cause definition changes including willful malfeasance standard.
- Cause definitions revised across both agreements: willful malfeasance/willful misconduct replaces material misconduct and gross negligence.
- Both amendments supersede prior employment agreements; terms approved by Compensation Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000110465923020220/0001104659-23-020220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000110465923020220/tm236705d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-020220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer